TY  - JOUR
AU  - Alemany, Regina
AU  - Moura, David S
AU  - Redondo, Andres
AU  - Martinez-Trufero, Javier
AU  - Calabuig, Silvia
AU  - Saus, Carlos
AU  - Obrador-Hevia, Antonia
AU  - Ramos, Rafael
AU  - Villar, Victor H
AU  - Valverde, Claudia
AU  - Vaz, Maria Angeles
AU  - Medina, Javier
AU  - Felipe-Abrio, Irene
AU  - Hindi, Nadia
AU  - Taron, Miguel
AU  - Martin-Broto, Javier
PY  - 2018
DO  - 10.1158/1078-0432.CCR-18-0851
UR  - http://hdl.handle.net/10668/12744
T2  - Clinical cancer research : an official journal of the American Association for Cancer Research
AB  - Purpose: Nilotinib plus doxorubicin showed to be synergistic regarding apoptosis in several sarcoma cell lines. A phase I/II trial was thus designed to explore the feasibility of nilotinib as coadjuvant of doxorubicin by inhibiting MRP-1/P-gp efflux...
LA  - en
KW  - Animals
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Apoptosis
KW  - Biomarkers, Tumor
KW  - Cell Line, Tumor
KW  - Cell Proliferation
KW  - Chemotherapy, Adjuvant
KW  - Doxorubicin
KW  - Drug Evaluation, Preclinical
KW  - Female
KW  - Humans
KW  - Male
KW  - Mice
KW  - Neoplasm Grading
KW  - Neoplasm Staging
KW  - Pyrimidines
KW  - Sarcoma
TI  - Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma.
TY  - research article
VL  - 24
ER  -